Phoenix Financial Ltd. Sells 4,524 Shares of Edwards Lifesciences Co. (NYSE:EW)

Phoenix Financial Ltd. lowered its stake in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 9.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 44,309 shares of the medical research company's stock after selling 4,524 shares during the period. Phoenix Financial Ltd.'s holdings in Edwards Lifesciences were worth $3,280,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Crowley Wealth Management Inc. acquired a new position in shares of Edwards Lifesciences in the 4th quarter worth approximately $26,000. Millstone Evans Group LLC bought a new position in Edwards Lifesciences in the 4th quarter valued at about $29,000. Migdal Insurance & Financial Holdings Ltd. bought a new stake in Edwards Lifesciences during the fourth quarter worth $30,000. Roble Belko & Company Inc bought a new position in shares of Edwards Lifesciences during the fourth quarter valued at about $46,000. Finally, Catalyst Capital Advisors LLC bought a new stake in Edwards Lifesciences during the fourth quarter worth $54,000. Institutional investors own 79.46% of the company's stock.

Edwards Lifesciences Price Performance

NYSE:EW traded up $0.69 during trading hours on Wednesday, reaching $71.45. 1,092,245 shares of the company's stock were exchanged, compared to its average volume of 4,897,280. The company has a market capitalization of $42.00 billion, a P/E ratio of 10.25, a price-to-earnings-growth ratio of 4.82 and a beta of 1.15. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $95.25. The business's 50-day simple moving average is $71.27 and its two-hundred day simple moving average is $70.76. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06.

Remove Ads

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. Sell-side analysts expect that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, Director Steven R. Loranger sold 5,739 shares of the firm's stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $76.42, for a total value of $438,574.38. Following the completion of the sale, the director now owns 60,372 shares in the company, valued at approximately $4,613,628.24. This trade represents a 8.68 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Donald E. Bobo, Jr. sold 9,500 shares of the firm's stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $67.96, for a total transaction of $645,620.00. Following the transaction, the vice president now owns 46,936 shares of the company's stock, valued at approximately $3,189,770.56. This represents a 16.83 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 72,353 shares of company stock worth $5,197,442 over the last 90 days. 1.29% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research firms recently commented on EW. Piper Sandler raised their price objective on shares of Edwards Lifesciences from $70.00 to $73.00 and gave the stock a "neutral" rating in a report on Wednesday, February 12th. Barclays lifted their price objective on Edwards Lifesciences from $88.00 to $90.00 and gave the stock an "overweight" rating in a report on Thursday, February 13th. Stifel Nicolaus upgraded shares of Edwards Lifesciences from a "hold" rating to a "buy" rating and raised their target price for the stock from $75.00 to $90.00 in a research note on Thursday, January 30th. Canaccord Genuity Group lifted their price objective on shares of Edwards Lifesciences from $68.00 to $71.00 and gave the stock a "hold" rating in a research note on Thursday, February 13th. Finally, Wolfe Research lowered shares of Edwards Lifesciences from a "hold" rating to a "strong sell" rating in a research note on Wednesday, February 12th. One investment analyst has rated the stock with a sell rating, fourteen have given a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat.com, Edwards Lifesciences has an average rating of "Hold" and a consensus price target of $78.55.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.